Cosmo Pharmaceuticals Achieves €104.2M Revenue and €9.5M EBITDA in 2025; Proposes €2.10 Dividend; Establishes 2026 Growth Framework

· Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals N.V. (“Cosmo”) today reports its audited financial results for the fiscal year ended December 31, 2025. The Company also publishes its 2025 Annual Report and ESG Report 2025, available on its corporate website under www.cosmohealthconfidence.com/key-financial-reports.

Download press release (PDF)

← All news